Articles tagged with Sars Cov 2
Scientists identify the Nsp1 protein as a key player in blocking host cell genes that promote viral replication. By inhibiting two steps in protein production, Nsp1 allows SARS-CoV-2 to replicate unchecked. This discovery provides a potential target for new COVID-19 therapies.
Scientists have developed a highly sensitive antibody test that can detect all known human coronaviruses, including new SARS-CoV-2 variants. The test uses 29 immune signatures specific to SARS-CoV-2 and has been validated with a high specificity and sensitivity rate.
Researchers found that high-dose zinc and ascorbic acid supplementation did not significantly impact symptom length or reduction among ambulatory patients with SARS-CoV-2 infection. The study suggests that treatment with these supplements may be ineffective against the virus.
The study found that serological tests detecting previous SARS-CoV-2 infection varied in their ability to accurately identify infected individuals. Researchers analyzed existing clinical data and identified factors influencing test performance.
The rise of several significant SARS-CoV-2 variants has sparked concerns about vaccine efficacy and prompted calls for a global approach to combatting the virus. Experts from the National Institute of Allergy and Infectious Diseases emphasize the need for robust surveillance, tracking, and vaccine deployment worldwide.
Researchers analyzed protein sequences to understand how SARS-CoV-2 infects cells, identifying short linear motifs involved in endocytosis and autophagy. The findings suggest potential new therapeutic approaches for COVID-19, including the use of existing drugs that interfere with these cellular processes.
A portable, suitcase-based laboratory provides rapid and accurate SARS-CoV-2 testing in regions with limited infrastructure. The mini-lab uses a recombinase polymerase amplification method, producing results in under 15 minutes.
A study published in PLOS Pathogens found that most people can produce neutralizing antibodies against SARS-CoV-2 in severe cases of COVID-19. These antibodies can be combined to block the virus from spreading, offering a promising approach for treatment and prevention, especially for vulnerable populations.
A new study from the University of Chicago found that asymptomatic cases contribute to community transmission, making up at least 50% of driving force of SARS-CoV-2 infection. This finding supports the crucial role of mask wearing and social distancing in reducing community transmission.
A new study has identified key differences in SARS-CoV-2 and SARS-CoV that affect their behavior, revealing crucial insights into the development of antiviral drugs. The findings suggest that current approaches to drug discovery may not be effective for COVID-19 treatment.
A CRISPR-based method was assessed for screening SARS-CoV-2 among asymptomatic college students. The study found that the method was effective in detecting the virus. The researchers used this approach to identify potential carriers of the virus.
Researchers at the University of Minnesota Medical School studied SARS-CoV-2 infections and found that remdesivir is effective in blocking virus replication in all cell types in the upper respiratory tract. The study also identified goblet cells as the main producer of pro-inflammatory responses, common in severe COVID-19 cases.
Researchers found that people with cross-reactive antibodies had no protection against SARS-CoV-2, and these antibodies did not correlate with COVID-19 severity. The study suggests that pre-existing immune responses may play a role in reducing disease severity, but more research is needed to confirm this.
Animals exhibit various social distancing behaviors to avoid disease transmission, including olfactory cues and avoidance of diseased individuals. This phenomenon provides insights into human responses to pandemics, emphasizing the importance of diagnostic testing for disease reduction.
Scientists at UNC-Chapel Hill used a new lab model containing human lung tissue to show that EIDD-2801 effectively halts SARS-CoV-2 replication and prevents infection of human cells. The drug also demonstrated significant reduction in viral shedding in COVID-19 patients.
A new study has detected high levels of neutralizing antibodies against SARS-CoV-2-related coronaviruses (SC2r-CoVs) in bats and pangolins in Southeast Asia. The discovery suggests that more SC2r-CoVs may be present in the region, with potential implications for future pandemics.
A study published in The Lancet Child & Adolescent Health found low SARS-CoV-2 seroprevalence rates among French daycare children, indicating minimal transmission within daycare centers. The rate of infection was approximately 3.7%, with positive cases likely infected by an adult household member.
New study by Uppsala University researchers identifies ACE2 and integrin beta3 as potential key players in SARS-CoV-2 cell infection. The proteins interact with cellular processes of uptake and disposal, suggesting hijacking during infection.
A study of 157 healthcare workers in Ekaterinburg, Russia found that aspirating systems with HEPA filters reduced SARS-CoV-2 infection prevalence. Dental clinics using dry suction systems had higher infection rates compared to those utilizing semi-dry and fully filtered systems.
A cluster of COVID-19 cases at Brigham and Women's Hospital was analyzed to understand the spread of the virus and identify effective control measures. Researchers found that a patient with pulmonary disease likely infected multiple staff members and patients, highlighting the importance of testing, masking, and eye protection.
Researchers found higher expression of genes critical for SARS-CoV-2 entry and immune response, increasing risk of severe illness and late-onset complications. People with Down syndrome may benefit from early vaccination to mitigate these risks.
The study found that a considerable percentage of the Virginia population had been exposed to SARS-CoV-2 following the initial outbreak of COVID-19. Researchers used this data to understand risk factors associated with the virus, contributing to better public health strategies.
A study analyzing Kaiser Permanente members found racial minorities more likely to test positive for COVID-19 than white patients, with Latino patients nearly 4 times as likely. Healthcare workers in Los Angeles expressed hesitancy about getting the COVID-19 vaccine, citing concerns over development and science.
A new study reveals climate change has altered habitats, driving growth of forest habitat favored by bats. This created a suitable environment for many bat species to harbor more types of bat-borne coronavirus, including SARS-CoV-2.
Scientists at the Francis Crick Institute have discovered structural similarities between SARS-CoV-2 and a pangolin coronavirus, suggesting that a pangolin coronavirus could infect humans. The study found that the pangolin virus was able to bind to receptors from both pangolins and humans.
Researchers observed SARS-CoV-2 mutating in a patient with compromised immune system treated with convalescent plasma. The virus developed key mutations similar to the new UK variant, making it more infectious on cells.
Researchers analyzed 851,199 listings from 30 dark web marketplaces, identifying 788 COVID-19 related products. The study highlights the importance of monitoring DWMs due to vaccine shortages and potential health risks.
A man in his 40s, treated for mild COVID-19 4 months after a severe initial bout, tested positive twice more. Experts suggest waning immunity may increase risk of reinfection, while milder symptoms second time around could be due to residual immunity from the first infection.
Researchers have developed three nonhuman primate species as potential models of SARS-CoV-2 airborne infection, which can be used to test vaccines and therapies. The studies found that cynomolgus macaques, rhesus macaques, and African green monkeys developed disease similar to mild acute respiratory disease in humans.
Researchers at Bielefeld University have successfully imaged SARS-CoV-2 coronavirus using a helium ion microscope, allowing direct observation of the virus's interaction with host cells. The study provides valuable information on the virus's defense mechanisms and potential treatment strategies.
Researchers analyzed 851,199 listings from 30 dark web marketplaces between Jan 2020 and Nov 2020 to identify COVID-19 related products. DarkBay/DBay emerged as a prominent platform offering COVID-19 specific listings.
A new DNA-based vaccine platform has been shown to induce potent immune responses in mice, generating high levels of antibodies and strong T cell responses. The vaccine was found to be immunogenic, efficiently neutralizing the SARS-CoV-2 virus after a single immunization.
Researchers discovered SARS-CoV-2 mutates by deleting small bits of its sequence, evading neutralizing antibodies. This pattern repeats itself in emerging variants like B.1.1.7, highlighting the need for multiple approaches to combat the virus.
Researchers develop peptide-based 'booster' inhibitors that use generic hepatitis B antibodies to neutralize SARS-CoV-2 viruses. This approach offers a rapid response time and could provide guidance for preparing generic therapeutics against emerging pathogens.
A Wayne State University research team is developing an artificial intelligence (AI) model to help identify severe SARS-CoV-2 illness in children. The project aims to predict disease severity and risk stratify patients, enabling early detection and timely intervention.
Researchers identified recurring deletions in SARS-CoV-2 spike protein that prevent antibody binding, allowing viruses to evade the immune system. The study analyzed nearly 150,000 gene sequences and found instances of viruses with these deletions, which have repeatedly arisen in genetically distinct viruses worldwide.
A new study reveals that adults between 20 and 49 years old are driving the resurgence of COVID-19 in the United States. The research suggests that lifting school closure mandates did not lead to significant increases in COVID-19 attributable deaths, contrary to initial concerns.
Researchers found that a significant proportion of international entrants to China test positive for asymptomatic SARS-CoV-2 infections. This study highlights the challenges in controlling the spread of COVID-19 through travel restrictions and testing.
Researchers from UTEP and Howard University discovered valuable data comparing fundamental mechanisms of SARS-CoV and SARS-CoV-2 to better understand how these viruses attack the human body. They found that mutations make SARS-CoV-2 significantly more contagious and prone to cause serious infections.
Researchers found that patients with mild COVID-19 symptoms have an early induction of IFN-γ secreting SARS-CoV-2 specific T cells, which plays a crucial role in rapid viral control and disease clearance. The study's findings have implications for vaccine design and monitoring.
This study examined the association between maternal and neonatal SARS-CoV-2-specific antibody concentrations, shedding light on neonatal immunity and maternal vaccination strategies. The findings provide valuable insights into the dynamics of maternal antibody responses to SARS-CoV-2 infection during pregnancy.
A new UC Riverside study examines how people experience everyday life and its situations before and during the coronavirus pandemic. The study found that some everyday experiences suffer, such as conversation and finding new relationships, but positive feelings remain largely unchanged due to individual personality.
Researchers analyzed 211 virus genomes and found nine local lineages circulating in Russia, not present elsewhere. The study suggests that the main channel of coronavirus 'import' was passenger traffic from European countries.
Researchers emphasize the importance of viral sequencing in understanding the spread and evolution of SARS-CoV-2. The technique has enabled the identification of new variants of concern and insights into transmission routes, but challenges remain in collecting and integrating metadata for genetic analyses.
The N439K mutation in the SARS-CoV-2 Spike protein confers resistance to serum antibodies and monoclonal antibodies, including those used in treatments. Researchers found that viruses with this mutation bind more strongly to the human ACE2 receptor, evading immunity while retaining infectivity.
A recent study published in Cell Report Medicine has provided a detailed look at the vulnerable sites on the novel coronavirus SARS-CoV-2 that T cells can attack. The research found that T cells can recognize dozens of epitopes on the virus, including several additional sites on the spike protein.
Northern Arizona University will test Allarity drug stenoparib against the highly infectious Coronavirus Variant B117, a variant found in the UK and US that spreads more easily than other variants. The testing aims to validate the antiviral activity of stenoparib against this variant.
A Johns Hopkins Medicine study profiles immune cells called T lymphocytes that fight COVID-19, identifying specific proteins recognized by these cells. The findings may help guide the development of next-generation vaccines.
A new study demonstrates that SARS-CoV-2 reacts to antibodies of other coronavirus strains and vice versa. However, antibodies from the 2003 SARS outbreak had only limited effectiveness in neutralizing the new virus.
A recent analysis by University of Ottawa faculty members finds legal justification for mandating SARS-CoV-2 vaccination for health care workers in public and private settings. The study highlights the importance of exemptions for individuals with underlying health issues or other reasons to ensure the protection of government mandates...
A new approach maps viral mutations that escape leading antibodies, revealing a single amino-acid mutation that fully escapes Regeneron's antibody cocktail. The maps show a substantial number of RBD mutations in circulation that escaped one or more antibodies.
Scientists engineered an antibody, ADG-2, that rivals current treatments and broadly neutralizes clade 1 sarbecoviruses, including SARS-CoV-2. This breakthrough represents a potential pan-SARS vaccine target.
A new electrical detector has been developed for the fast and accurate detection of SARS-CoV-2 RNA and antibodies, allowing for rapid point-of-care testing with a turn-around time of around 10 minutes. The device uses graphene field-effect transistors to detect RNA and offers an ultra-low limit of detection of 0.1 fg/mL.
ADG2 demonstrates comparable or higher neutralization potency against SARS-CoV-2 than leading antibodies in development for COVID-19. It binds effectively to all commonly circulating SARS-CoV-2 variants and shows broad neutralizing activity against SARS-CoV and related coronaviruses.
In preclinical studies, plitidepsin outperforms Remdesivir in inhibiting SARS-CoV-2 replication and viral load, offering a potential new therapy for COVID-19 treatment. Further clinical trials are warranted to evaluate its effectiveness in humans.
A review of 61 studies confirms that at least 1 in 3 people infected with SARS-CoV-2 do not exhibit symptoms, suggesting widespread testing can help identify asymptomatic spreaders. The findings also underscore the importance of determining vaccine effectiveness against asymptomatic infections.
Researchers Yuntao Wu and Ramin Hakami are investigating COVID-19 therapies using the K18-hACE2 mouse model, which can replicate severe COVID-19 infection in humans. The study aims to test the efficacy of therapeutics developed by Dejia Harmony against COVID-19.
Research suggests that non-steroidal anti-inflammatory drugs (NSAIDs) can dampen the immune response to SARS-CoV-2 infection. This could have implications for COVID-19 treatment and vaccination strategies. The findings also highlight the need for further evaluation of NSAID use during natural infections and vaccinations.
A large observational study found SARS-CoV-2 infection was particularly low among children aged 1 to 10 years old in southwest Germany. The study highlights the effectiveness of mass testing in informing pandemic decision-making.
Researchers explore ECMO and CRRT treatment in critically ill SARS-CoV-2 pneumonia patients, achieving a 100% survival rate for those with cardiopulmonary failure. The combined therapy is deemed an important treatment technique for critically ill patients.